SEARCH

SEARCH BY CITATION

REFERENCES

  • Aikawa T, Segre GV, Lee K. 2001. FGF inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-Cdk2. J Biol Chem 276: 2934729352.
  • Anderson J, Burns HD, Enriquez-Harris P, Wilkie AM, Heath JK. 1998. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum Mol Genet 7: 14751483.
  • Baker CV, Bronner-Fraser M. 1997. The origins of the neural crest. I. Embryonic induction. Mech Dev 69: 311.
  • Burke D, Wilkes D, Blundell TL, Malcolm S. 1998. Fibroblast growth factor receptors: lessons from the genes. Trends Biochem Sci 23: 5962.
  • Christiansen JH, Coles EG, Wilkinson DG. 2000. Molecular control of neural crest formation, migration and differentiation. Curr Opin Cell Biol 12: 719724.
  • Cohen MM. 1993. Sutural biology and the correlates of craniosynostosis. Am J Med Genet 47: 581616.
  • Couly GF, Coltey PM, Le Douarin NM. 1993. The triple origin of skull in higher vertebrates: a study in quail-chick chimeras. Development 117: 409429.
  • Debiais F, Hott M, Graulet AM, Marie PJ. 1998. The effects of fibroblast growth factor-2 on human neonatal calvaria osteoblastic cells are differentiation stage specific. J Bone Miner Res 13: 645654.
  • Fragale A, Tartaglia M, Bernardini S, Di Stasi AM, Di Rocco C, Velardi F, Teti A, Battaglia PA, Migliaccio S. 1999. Decreased proliferation and altered differentiation in osteoblasts from genetically and clinically distinct craniosynostotic disorders. Am J Pathol 154: 14651477.
  • Galvin BD, Hart KC, Meyer AN, Webster MK, Donoghue DJ. 1996. Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras. Proc Natl Acad Sci U S A 93: 78947899.
  • Hart SL, Arancibia-Carcamo CV, Wolfert MA, Mailhos C, O'Reilly NJ, Ali RR, Coutelle C, George AJ, Harbottle RP, Knight AM, Larkin DF, Levinsky RJ, Seymour LW, Thrasher AJ, Kinnon C. 1998. Lipid-mediated enhancement of transfection by a nonviral integrin-targeting vector. Hum Gene Ther 9: 575585.
  • Henderson JE, Naski MC, Aarts MM, Wang D, Cheng L, Goltzman D, Ornitz DM. 2000. Expression of FGFR3 with the G380R achondroplasia mutation inhibits proliferation and maturation of CFK2 chondrocytic cells. J Bone Miner Res 15: 155165.
  • Howard TD, Paznekas WA, Green ED, Chiang LC, Ma N, Rosa FW, Delgado CG, Gonzalez-Ramos M, Kline AD, Jabs EW. 1997. Mutations in TWIST, a basic helix loop helix transcription factor, in Saethre-Chotzen syndrome. Nat Genet 15: 3641.
  • Iseki S, Wilkie AOM, Heath JK, Ishimaru T, Eto K, Morriss Kay GM. 1997. Fgfr2 and osteopontin domains in the developing skull vault are mutually exclusive and can be altered by locally applied FGF2. Development 124: 33753384.
  • Iseki S, Wilkie AO, Morriss-Kay GM. 1999. Fgfr1 and Fgfr2 have distinct differentiation- and proliferation-related roles in the developing mouse skull vault. Development 126: 56115620.
  • Jabs EW, Müller U, Li X, Ma L, Luo W, Haworth IS, Klisak I, Sparkes R, Warman ML, Muliken JB, Snead ML, Maxson R. 1993. A mutation in the homeodomain of human MSX2 gene in a family affected with autosomal dominant craniosynostosis. Cell 75: 443450.
  • Kim H-J, Rice DPC, Kettunen PJ, Thesleff I. 1998. FGF-, BMP- and Shh-mediated signalling pathways in the regulation of cranial suture morphogenesis and calvarial bone development. Development 125: 12411251.
  • Le Douarin N. 1999. The neural crest. Cambridge: Cambridge University Press. p 1445
  • Le Douarin NM, Ziller C, Couly GF. 1993. Patterning of neural crest derivatives in the avian embryo: in vivo and in vitro studies. Dev Biol 159: 2449.
  • Legeai-Mallet L, Benoist-Lasselin C, Delezoide AL, Munnich A, Bonaventure J. 1998. Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. J Biol Chem 273: 1300713014.
  • Lemonnier J, Delannoy P, Hott M, Lomri A, Modrowski D, Marie PJ. 2000. The Ser252Trp fibroblast growth factor receptor-2 (FGFR-2) mutation induces PKC-independent downregulation of FGFR-2 associated with premature calvaria osteoblast differentiation. Exp Cell Res 256: 158167.
  • Lomri A, Lemonnier J, Hott M, de Parseval N, Lajeunie E, Munnich A, Renier D, Marie PJ. 1998. Increased clavaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert Syndrome. J Clin Invest 101: 13101317.
  • Mansukhani A, Bellosta P, Sahni M, Basilico C. 2000. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Cell Biol 149: 12971308.
  • Mohammadi M, Dionne CA, Li W, Li N, Spivak T, Honegger AM, Jaye M, Schlessinger J. 1992. Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis. Nature 358: 681684.
  • Moore RL, Ferretti P, Copp A, Thorogood P. 2002. Blocking endogenous FGF-2 activity prevents cranial osteogenesis. Dev Biol 243: 99114. (Published electronically 23rd January 2002 doi:10.1006/dbio. 2001.0533).
  • Morgan BA Fekete DM. 1996. Manipulating gene expression with replication-competent retroviruses. Methods Cell Biol 51: 185218.
  • Naski MC, Wang Q, Xu J, Ornitz DM. 1996. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 13: 233237.
  • Naski MC, Colvin JS, Coffin JD, Ornitz DM. 1998. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 125: 49774988.
  • Noden DM. 1983. The role of the neural crest in patterning of avian cranial skeletal, connective, and muscle tissues. Dev Biol 96: 144165.
  • Oldridge M, Wilkie AOM, Slaney SF, Poole MD, Pulleyn LJ, Rutland P, Hockley AD, Wake MJC, Goldin JH, Winter RM, et al. 1995. Mutations in the third immunoglobulin domain of the fibroblast growth factor receptor-2 gene in Crouzon syndrome. Hum Mol Genet 4: 10771082.
  • Passos-Bueno MR, Wilcox WR, Jabs EW, Sertie AL, Alonso LG, Kitoh H. 1999. Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat 14: 115125.
  • Peters KG, Marie J, Wilson E, Ives HE, Escobedo J, Del Rosario M, Mirda D, Williams LT. 1992. Point mutation of an FGF receptor abolishes phosphatidylinositol turnover and Ca2+ flux but not mitogenesis. Nature 358: 678681.
  • Robertson SC, Meyer AN, Hart KC, Galvin BD, Webster MK, Donoghue DJ. 1998. Activating Mutations in the Extracellular Domain of FGFR2 Function by Disruption of the Ig-3 Disulfide Bond. Proc Natl Acad Sci U S A 95: 45674572.
  • Sahni M, Ambrosetti DC, Mansukhani A, Gertner R, Levy D, Basilico C. 1999. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev 13: 13611366.
  • Sahni M, Raz R, Coffin JD, Levy D, Basilico C. 2001. STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. Development 128: 21192129.
  • Sarkar S, Petiot A, Copp A, Ferretti P, Thorogood P. 2001. FGF-2 promotes skeletogenic differentiation of cranial neural crest cells. Development 128: 21432152.
  • Segev O, Chumakov I, Nevo Z, Givol D, Madar-Shapiro L, Sheinin Y, Weinreb M, Yayon A. 2000. Restrained chondrocyte proliferation and maturation with abnormal growth plate vascularization and ossification in human FGFR-3(G380R) transgenic mice. Hum Mol Genet 9: 249258.
  • Selleck MA, Scherson TY, Bronner Fraser M. 1993. Origins of neural crest cell diversity. Dev Biol 159: 111.
  • Swartz M, Eberhart J, Mastick GS, Krull CE. 2001. Sparking new frontiers: using in vivo electroporation for genetic manipulations. Dev Biol 233: 1321.
  • Tavormina PL, Shiang R, Thompson LM, Zhu YZ, Wilkin DJ, Lachman RS, Wilcox WR, Rimoin DL, Cohn DH, Wasmuth JJ. 1995. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 9: 321328.
  • Webster MK Donoghue DJ. 1996. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J 15: 520527.
  • Webster MK, Donoghue DJ. 1997a. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet 13: 178182.
  • Webster MK, Donoghue DJ. 1997b. Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain. Mol Cell Biol 17: 57395747.
  • Webster MK, D'Avis PY, Robertson SC, Donoghue DJ. 1996. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol Cell Biol 16: 40814087.
  • Weimin B, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B. 1999. Sox9 is required for cartilage formation. Nat Genet 22: 8589.
  • Yu K, Herr AB, Waksman G, Ornitz DM. 2000. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc Natl Acad Sci U S A 97: 1453614541.